SC
RXRX icon

SummitTX Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

SummitTX Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.3K Buy
+25,963
New +$86.4K ﹤0.01% 740
2025
Q2 		– Sell
-14,620
Closed -$77.3K – 980
2025
Q1 		$77.3K Buy
+14,620
New +$107K ﹤0.01% 765

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SummitTX Capital's RXRX Position: Q2 2026 in Review

SummitTX Capital opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 25,963 shares worth $95.3K. The stake represents ﹤0.01% of the portfolio and ranks #740 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in RXRX as recently as Q1 2025.

SummitTX Capital first reported a position in RXRX in Q1 2025 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • SummitTX Capital held 25,963 shares of Recursion Pharmaceuticals worth $95.3K as of Q2 2026.
  • Recursion Pharmaceuticals was a new SummitTX Capital position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of SummitTX Capital's portfolio in Q2 2026, its #740 holding.
  • SummitTX Capital first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.